Lead Investigator: Kazuki Takada, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
Title of Proposal Research: Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy A Post Hoc Analysis of IMpower133
Vivli Data Request: 9244
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Small-Cell Lung Cancer (SCLC) represents about 10-15% of all lung cancers and is a rapidly progressing and challenging type to treat. The 5-year survival rate for this disease is very low, and due to the difficulty of early diagnosis, many cases are already advanced by the time of detection. Limited-stage SCLC presents only on one side of the chest and extensive-stage SCLC (ES-SCLC) has spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, or to other parts of the body (including the bone marrow). ES-SCLC remains an important challenge in oncology, as reported in the IMpower133 clinical trial, in which the immune checkpoint inhibitor atezolizumab (checkpoint inhibitors are immunotherapy drugs that stop tumors from evading white blood cells and stimulate an immune response against the tumor cells) was combined with carboplatin and etoposide (types of chemotherapy drugs which attach to tumor cells and stop them growing and dividing), has brought new hope to these patients. However, the prognosis of ES-SCLC remains poor and further treatment development is urgently needed to improve prognosis.
In recent years, it has been suggested that the gut microbiota (microorganisms that live in the digestive tract) plays a pivotal role in determining the efficacy of immunotherapy in many carcinomas. However, the interaction of the gastrointestinal environment, particularly the influence of probiotics (foods or supplements that contain live microorganisms intended to maintain or improve the “good” bacteria in the body), on the efficacy of cancer immunotherapy in ES-SCLC is not well understood.
The aim of this post hoc analysis of the IMpower133 clinical trial data is to ascertain the impact of probiotics on the clinical outcomes in patients with ES-SCLC treated with first-line atezolizumab combination therapy.
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02763579
Sponsor ID: GO30081